Remission, relapse, and re-remission of proliferative @entity1988 treated with @entity786 . BACKGROUND: Long-term intravenous @entity786 (IVC) in combination with @entity288 is standard therapy for proliferative @entity1988 , but it has limitations. There are few data on long-term remission rates, predictors of relapse, and the ability to achieve a second remission with currently recommended IVC regimens. METHODS: A cohort of 85 @entity1 with @entity1988 (focal N = 33, diffuse N = 52) treated with IVC was assembled in three institutions. Timing and predictors of remission, relapse, and re-remission were evaluated with Kaplan-Meier analyses and Cox models. RESULTS: The median time to remission was 10 months, whereas an estimated 22% of @entity1 had not remitted after 2 years. The median time to relapse among 63 @entity1 who had achieved remission was 79 months. In multivariate models, adverse predictors of remission were a delay in the initiation of therapy from the time @entity1310 was clinically diagnosed [hazard ratio (HR) 0.58, P = 0. 063] and a higher amount of @entity644 (HR 0.86 per 1 g/24 hours, P = 0.014). Predictors of earlier relapse for @entity1 entering remission included a longer time to remission (HR 1.029 per month, P = 0.025), a history of central nervous system involvement (HR 8.41, P = 0.002), and World Health Organization histology (P = 0.01). Among the 23 @entity1 who relapsed during follow-up, the median time to re-remission was 32 months, and with three exceptions, all @entity1 took substantially longer time to remit the second time compared with their first remission (P = 0.01). The time to re-remission was longer in @entity1 who had taken longer to remit the first time (HR 0.979 per month, P = 0.16), in @entity1 who had relapsed earlier after the first remission (HR 1.071 per month, P = 0.002), and in those with evidence of chronicity in the original kidney biopsy (P = 0.015). CONCLUSIONS: Prolonged courses with a cumulative risk of @entity137 are needed to achieve remission in many first-treated @entity1 and in most @entity1 treated for a second time. The optimal management of @entity1 with identified adverse predictors of response needs further study.

Remission, relapse, and re-remission of proliferative XXXX treated with @entity786 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity1310 :: ('MESH:D009393', 'Disease') :: ['nephritis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1988 :: ('MESH:D008181', 'Disease') :: ['lupus nephritis', 'proliferative lupus glomerulonephritis'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity1988 :: (MESH:D008181,Disease) :: ['lupus nephritis']
